"Drug Approval" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.
Descriptor ID |
D017277
|
MeSH Number(s) |
E05.337.300 I01.880.604.605.250.250
|
Concept/Terms |
Drug Approval- Drug Approval
- Approval, Drug
- Approvals, Drug
- Drug Approvals
- Food and Drug Administration Drug Approval
Drug Approval Process- Drug Approval Process
- Approval Process, Drug
- Approval Processes, Drug
- Drug Approval Processes
- Process, Drug Approval
- Processes, Drug Approval
New Drug Approval- New Drug Approval
- Approval, New Drug
- Approvals, New Drug
- Drug Approval, New
- Drug Approvals, New
- New Drug Approvals
|
Below are MeSH descriptors whose meaning is more general than "Drug Approval".
Below are MeSH descriptors whose meaning is more specific than "Drug Approval".
This graph shows the total number of publications written about "Drug Approval" by people in this website by year, and whether "Drug Approval" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 1 | 0 | 1 |
2001 | 0 | 1 | 1 |
2002 | 1 | 0 | 1 |
2004 | 1 | 2 | 3 |
2005 | 3 | 0 | 3 |
2006 | 4 | 1 | 5 |
2007 | 1 | 0 | 1 |
2008 | 0 | 1 | 1 |
2009 | 1 | 0 | 1 |
2010 | 2 | 1 | 3 |
2011 | 1 | 0 | 1 |
2012 | 2 | 0 | 2 |
2013 | 2 | 0 | 2 |
2014 | 0 | 1 | 1 |
2016 | 0 | 2 | 2 |
2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Approval" by people in Profiles.
-
FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer. Clin Cancer Res. 2021 04 15; 27(8):2126-2129.
-
Oral Anticoagulants: The Move Beyond Warfarin. J Neurosci Nurs. 2016 Jul-Aug; 48(4):177.
-
Generic medications for hepatitis C. Liver Int. 2016 07; 36(7):925-8.
-
Oral anticoagulants: the move beyond warfarin. J Neurosci Nurs. 2014 Oct; 46(5):253-5.
-
The FDA, bridging data, and hepatitis C. Hepatology. 2013 Mar; 57(3):875-7.
-
Conflating the approval process and clinical research with pharmacoeconomic evaluation. Am J Ther. 2013 Jan; 20(1):1.
-
Proposed accelerated FDA approvals for special medical use. Am J Ther. 2012 Nov; 19(6):393-4.
-
Making America more competitive: a paradigm shift in drug and device development. Am J Ther. 2012 Sep; 19(5):315-6.
-
Has the food and drug administration changed the drug approval process? Am J Ther. 2011 May; 18(3):179.
-
The Food and Drug Administration's paternalism. Am J Ther. 2010 Nov-Dec; 17(6):533-4.